Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
Open Access
- 7 March 2024
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 32 (5) , 1202-1218
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Swedish Orphan Biovitrum
- Vertex Pharmaceuticals Incorporated
This publication has 89 references indexed in Scilit:
- Sickle Cell DiseaseJAMA, 2022
- Off-target effects of base editors: what we know and how we can reduce itCurrent Genetics, 2021
- Genome editing approaches to β-hemoglobinopathies2021
- CRISPR-Cas12a: Functional overview and applicationsBiomedical Journal, 2020
- Advances in the Treatment of Sickle Cell DiseaseMayo Clinic Proceedings, 2018
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobinCurrent Opinion in Genetics & Development, 2015
- Development and Applications of CRISPR-Cas9 for Genome EngineeringCell, 2014
- Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic ElementsJournal of Molecular Evolution, 2005
- Perspectives for gene therapy: Inserting new genetic information into mammalian cells by physical techniques and viral vectorsPharmacology & Therapeutics, 1985